source
- Boehringer presents phase 1b data on obrixtamig showing strong response rates in second-line small cell lung cancerBoehringer Ingelheim presented updated data from its DAREON-9 phase 1b trial at the ESMO Congress in Madrid, evaluating the DLL3xCD3 bispecific T-cell engager obrixtamig in combination with topotec…
- Abbott to separate Nutrition business into independent publicly traded companyAbbott announced it will separate its Nutrition business into a stand-alone publicly traded company. The spin‑off will be carried out via a tax‑free distribution of the new company's shares to Abb…